BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
56.21
+0.71 (1.28%)
At close: Apr 6, 2026, 4:00 PM EDT
55.04
-1.17 (-2.08%)
After-hours: Apr 6, 2026, 5:53 PM EDT
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,221 employees as of December 31, 2025. The number of employees increased by 181 or 5.95% compared to the previous year.
Employees
3,221
Change (1Y)
181
Growth (1Y)
5.95%
Revenue / Employee
$1,000,079
Profits / Employee
$108,321
Market Cap
10.81B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,221 | 181 | 5.95% |
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | 3,001 | 152 | 5.34% |
| Dec 31, 2018 | 2,849 | 268 | 10.38% |
| Dec 31, 2017 | 2,581 | 288 | 12.56% |
| Dec 31, 2016 | 2,293 | 135 | 6.26% |
| Dec 31, 2015 | 2,158 | 477 | 28.38% |
| Dec 31, 2014 | 1,681 | 340 | 25.35% |
| Dec 31, 2013 | 1,341 | 252 | 23.14% |
| Dec 31, 2012 | 1,089 | 87 | 8.68% |
| Dec 31, 2011 | 1,002 | 131 | 15.04% |
| Dec 31, 2010 | 871 | 151 | 20.97% |
| Dec 31, 2009 | 720 | 71 | 10.94% |
| Dec 31, 2008 | 649 | 124 | 23.62% |
| Dec 31, 2007 | 525 | 115 | 28.05% |
| Dec 31, 2006 | 410 | 96 | 30.57% |
| Dec 31, 2005 | 314 | -45 | -12.53% |
| Dec 31, 2004 | 359 | 87 | 31.99% |
| Dec 31, 2003 | 272 | 53 | 24.20% |
| Dec 31, 2002 | 219 | 3 | 1.39% |
| Dec 31, 2001 | 216 | 42 | 24.14% |
| Dec 31, 2000 | 174 | 25 | 16.78% |
| Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 925 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| Vaxcyte | 507 |
BMRN News
- 17 days ago - Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
- 21 days ago - BioMarin stops mid-stage trials of bone disorder treatment - Reuters
- 25 days ago - BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - PRNewsWire
- 5 weeks ago - U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) - PRNewsWire
- 5 weeks ago - BioMarin to Participate in Four Upcoming Investor Conferences in March - PRNewsWire
- 6 weeks ago - BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results - PRNewsWire
- 6 weeks ago - BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET - PRNewsWire
- 7 weeks ago - BioMarin Announces Closing of Private Offering of Senior Notes - PRNewsWire